The short version of adipose tissue fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-16. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
At the 1922 and 1923 elections, the Liberals won barely a third of the vote and only a quarter of the seats in the House of Commons as many radical voters abandoned the divided Liberals and went over to Labour. In 1922, Labour became the official opposition. A reunion of the two warring factions took place in 1923 when the new Conservative prime minister Stanley Baldwin committed his party to protective tariffs, causing the Liberals to reunite in support of free trade. The party gained ground in the 1923 general election but made most of its gains from Conservatives whilst losing ground to Labour—a sign of the party's direction for many years to come. The party remained the third largest in the House of Commons, but the Conservatives had lost their majority. There was much speculation and fear [by whom?] about the prospect of a Labour government and comparatively little about a Liberal government, even though it could have plausibly presented an experienced team of ministers compared to Labour's almost complete lack of experience as well as offering a middle ground that could obtain support from both Conservatives and Labour in crucial Commons divisions. However, instead of trying to force the opportunity to form a Liberal government, Asquith decided instead to allow Labour the chance of office in the belief that they would prove incompetent, and this would set the stage for a revival of Liberal fortunes at Labour's expense, but it was a fatal error.
Histology image: 07903loa – Histology Learning System at Boston University - "Eye: fovea, RPE" Histology image: 08103loa – Histology Learning System at Boston University - "Integument: pigmented skin" UMass Amherst Libraries (2016-04-29). 7. Pigment Transfer in Skin Cells. Retrieved 2026-05-20 – via YouTube.
By this time, even South Africa's John Vorster had come to this view. While Vorster remained confident of continued white minority rule in South Africa, he concluded that a similar political system was not sustainable in Rhodesia, a country where black people outnumbered white people 22:1. In 1976, the population included 270,000 white Rhodesians of European descent and six million black Africans. International business groups involved in the country (e.g. Lonrho) transferred their support from the Rhodesian government to black nationalist parties. Business leaders and politicians feted Nkomo on his visits to Europe. ZANU also attracted business supporters who saw the course that future events were likely to take. Funding and arms support provided by supporters, particularly from the Soviet Union and its allies in the latter 1970s, allowed both ZIPRA and the ZANLA to acquire more sophisticated weaponry, thereby increasing the military pressure that the guerrillas were able to place on Rhodesia. Until 1972, containing the guerrillas was little more than a police action. Even as late as August 1975 when Rhodesian government and black nationalist leaders met at Victoria Falls for negotiations brokered by South Africa and Zambia, the talks never got beyond the procedural phase. Rhodesian representatives made it clear they were prepared to fight an all out war to prevent majority rule. However, the situation changed dramatically after the end of Portuguese colonial rule in Mozambique in 1975.
Sources: en.wikipedia.org
=== General topics === Biological engineering Biomolecular engineering Chemical engineering Chemistry Electrical engineering Materials science and engineering Mechanical engineering Molecular design software Molecular electronics Molecular modeling Molecular nanotechnology Nanotechnology
=== Endothermy === Nearly all mammals are endothermic ("warm-blooded"). Most mammals also have hair to help keep them warm. Like birds, mammals can forage or hunt in weather and climates too cold for ectothermic ("cold-blooded") reptiles and insects. Endothermy requires plenty of food energy, so mammals eat more food per unit of body weight than most reptiles. Small insectivorous mammals eat prodigious amounts for their size. A rare exception, the naked mole-rat produces little metabolic heat, so it is considered an operational poikilotherm. Birds are also endothermic, so endothermy is not unique to mammals.
=== Animal rights === Barker was a vegetarian. In 1982, Barker began ending The Price Is Right episodes with the phrase: "This is Bob Barker reminding you to help control the pet population – have your pets spayed or neutered." Though Barker had already been dabbling in animal rights before meeting Burnet, his efforts became more aggressive during his relationship with her. In 1987, Barker requested the removal of fur prizes for the Miss USA pageant and stepped down as host when the producers refused. In 1989, Barker and United Activists for Animal Rights publicly accused several media projects and the American Humane Association of animal mistreatment and condoning animal mistreatment, a tactic which resulted in a $10 million suit against him and the UAAR for libel, slander, and invasion of privacy. The suit was finally settled by the insurer in 1994. Barker founded DJ&T Foundation in 1994, named after his late wife and mother, which has contributed millions of dollars to animal-neutering programs and funded animal rescue and park facilities all over the United States. In 2004, Barker donated $1 million (equivalent to $1.7 million in 2025) to Columbia Law School to support the study of animal rights. In 2009, Barker wrote a letter about three businesses in Cherokee, North Carolina, asking them to close their bear exhibits. He threatened to not attend the 2009 Game Show Awards, where Barker was to receive a lifetime achievement award, because Betty White would be attending.
ascorbateside 1 + Fe(III)side 2 = monodehydroascorbateside 1 + Fe(II)side 2 In which the enzyme only transports an electron in the catalysation of an oxidoreductase reaction between a molecule and an inorganic cation located on different sides of the membrane.
Sources: en.wikipedia.org
=== Brain === Broad generalizations are often made in popular psychology about certain brain functions being lateralized, or more predominant in one hemisphere than the other. These claims are often inaccurate or overstated. The human brain, particularly the prefrontal cortex, does not reach "full maturity" or "full development" at any particular age (e.g. 16, 18, 21, 25, 30). Changes in structure and myelination of gray matter are recorded to continue with relative consistency all throughout life including until death. Different mental abilities peak earlier or later in life. Humans do not generate all of the brain cells they will ever have by the age of two years. Although this belief was held by medical experts until 1998, it is now understood that new neurons can be created after infancy in some parts of the brain into late adulthood. People do not use only 10% of their brains. While it is true that a small minority of neurons in the brain are actively firing at any one time, a healthy human will normally use most of their brain over the course of a day, and the inactive neurons are important as well. The idea that activating 100% of the brain would allow someone to achieve their maximum potential and/or gain various psychic abilities is common in folklore and fiction, but doing so in real life would likely result in a fatal seizure. This misconception was attributed to late 19th century leading thinker William James, who apparently used the expression only metaphorically.
Everyone always asks if that is Demri Parrott on the Dirt Cover. I think Demri's name might have been mentioned as a possible model once or twice, but it was never a serious consideration. In an interview with the Canadian magazine M.E.A.T. in December 1992, Layne Staley said about the cover:
Overall, according to a study in British Columbia, approximately 2.3 children per 100,000 births (1 in 43,000) have some form of glycogen storage disease. In the United States, they are estimated to occur in 1 per 20,000–25,000 births. Dutch incidence rate is estimated to be 1 per 40,000 births. While a Mexican incidence showed 6.78:1000 male newborns. Within the category of muscle glycogenoses (muscle GSDs), McArdle disease (GSD-V) is by far the most commonly diagnosed.
Ellen McLain (born 1952 or 1953) is an American voice actress. She is best known for providing the voice of GLaDOS, the primary antagonist of the Portal video game series, the Combine Overwatch AI in Half-Life 2, and the Administrator, the announcer in Team Fortress 2. Her voice roles also include the Jaeger A.I. in Pacific Rim and The Witch in Left 4 Dead 2.
== Gastrointestinal == The gastrointestinal tract has multiple trophic factors that regulate growth. The gut contains peptides that stimulate mucosal growth of stomach, colon, and small bowl cells. The hormones secreted control other gastrointestinal functions like regulation of secretion, motility, digestion and absorption.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.